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Zvavahera M Chirenje§,1, Benoı̂t R Mâsse2, Lisa A Maslankowski3, Gita Ramjee4, Anne S Coletti5,
Tchangani N Tembo6, Tsitsi M Magure1, Lydia Soto-Torres7, Cliff Kelly2, Sharon Hillier8 and Abdool Karim9
§Corresponding author: Zvavahera M Chirenje, University of Zimbabwe  Department of Obstetrics and Gynaecology, College of Health Sciences, P.O. Box A178,
Avondale, Harare, Zimbabwe. (chirenje@uz-ucsf.co.zw)
Abstract
Background: The majority of new HIV infections are acquired through heterosexual transmission. There is urgent need for
prevention methods to compliment behavior change and condom use. Topical microbicide represent a potential strategy for
reduction of HIV transmission in women.
Methods:Monthly Colposcopy evaluations were performed during pelvic examinations among 299 women enrolled in the Phase
2 portion of HPTN 035 study at four sites (1 in USA, 3 in Southern Africa). This was a phase 2/2b, multisite, randomized, and
controlled clinical trial with four arms: BufferGel, 0.5% PRO2000 Gel, placebo gel and no gel. At two of the sites, pelvic
examinations were conducted by the use of naked eye without colposcopy.
Results: A colposcopy finding of any kind was detected in 48% of participants at baseline compared to 40% at 3 months
(p=0.04). The lower rates were also observed in vaginal discharge (22% at baseline, 16% at 3 months, p=0.06), erythema (15%
at baseline, 8% at 3 months, p=0.004). The trend towards significance at p=0.05 disappear when utilizing stringent statistical
significance levels. A pelvic finding of any kind was detected in 71% of colposcopy participants compared to 41% of participants
who had naked eye examination only conducted at two sites that performed both colposcopy and naked eye without
colposcopy. Use of colposcopy yielded significantly higher rates of participants with deep epithelial disruption, erythema and
ecchymosis. We observed no cases of incident Chlamydia, Gonorrhea, or Syphilis during the three month follow up. There were 2
cases of incident HIV during 3-month study period neither of which was associated with any abnormal colposcopy evaluation
findings.
Conclusion: No safety signals were observed in the 4 study arms, allowing seamless transition from phase 2 to 2b. Colposcopy
utility in microbicide clinical trials has minimal value given high rates of background noise findings of no relevant clinical
significance.
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Background
The AIDS epidemic continues to spread relentlessly, with an
estimate of 2.7 million (2.4 to 2.9 million) new HIV infections
in 2010 [1]. The majority of these infections are acquired
through heterosexual transmission.
Condoms when used correctly and consistently can
provide high level of protection against HIV and other
sexually transmitted infections (STIs). However, negotiating
male condom use is not always feasible for many women,
and use of female condom requires the cooperation of the
male partner [2,3]. Advances in developing an effective HIV
vaccine have been slow with both setbacks [4] and interest-
ing modest results [5]. While there is an ongoing need
to scale up known effective prevention measures, there
remains a clear need for new technologies to prevent sexual
transmission of HIV, particularly for acceptable, affordable,
female-controlled prevention methods.
Topical microbicides are chemicals applied to the vagina
or rectal mucosa to prevent HIV and STI transmission. The
development of vaginal microbicides experienced setbacks
when earlier trials with nonoxynol-9 (N-9) formulations
showed paradoxically increased risk of HIV acquisition. This
increased risk of HIV transmission has been ascribed to the
observation that N-9 causes mucosal erosions and ulceration,
which can create potential entry portals for HIV [6,7]. In the
light of N-9 results, evaluation of integrity of genital
epithelium has become an essential step in the development
of topical microbicides.
Most drug regulatory authorities require a stringent path-
way for microbicide development including preclinical testing
that traditionally evaluates local safety in a rabbit vaginal
irritation model [8], but this has not always correlated well
with human genital tract epithelium toxicity events as seen in
the N-9 and cellulose sulphate clinical results [7,9]. The utility
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of colposcopy which allows low magnification (4 to 10X) of
genital tract was introduced by researchers to assist in
identifying potential microbicide-induced epithelium injuries
allowing stoppage of testing potential microbicide candidate
in phases 1 or 2.
BufferGel contains carbopol 974 P, a gelling agent that
provides buffering action and enhances body’s natural de-
fences by maintaining a low vaginal pH, and 0.5% PRO 2000
Gel is an HIV entry inhibitor. Both BufferGel and 0.5% PRO
2000 Gel underwent phase 1 clinical trials in several countries
showing no safety concerns and good acceptability [10,11].
HPTN 035 evaluated the safety and effectiveness of
BufferGel and 0.5% PRO 2000 Gel, and this trial showed
that 0.5% PRO 2000 reduced the incidence of HIV by a
modest 30% (p0.10) [12], but a subsequent phase 3 MDP
301 trial found PRO 2000 not to be protective against
HIV infection [13]. We report on the findings of utility of
colposcopic examinations performed during HPTN 035 study,
to assess the impact of the two candidate microbicides on
the genital epithelium and mucosa.
Methods
HPTN 035 study was as a phase 2/2b, multisite, randomized,
controlled clinical trial with four arms: BufferGel, 0.5% PRO
2000 Gel, placebo gel and no gel. A total of 3099 sexually
active HIV uninfected women from seven sites in six
countries were assigned to the four study treatment groups
in a 1:1:1:1 ratio. The three study gel arms were double-
blinded; participants assigned to these arms were instructed
to apply study gel intravaginally up to one hour before each
sex act [12].
The study (NCT 0074425) was approved by each site’s
Institutional Review Board(s) and drug regulatory authorities.
Women were eligible for enrolment if they were sexually
active, in good general health, aged 18 or older, not infected
with HIV and STIs, not pregnant, and willing and able to
provide informed consent for study participation. Women
who were diagnosed at screening with an STI received
treatment and were required to be symptom free at
enrolment. Pap smears were performed at screening and
the last quarterly visit with treatment of abnormal pap
smears as per local standard of care at selected sites that had
the facilities. Sites without facilities to perform and treat
women with abnormal pap smears did not participate in the
colposcopic evaluations phase 2 portion of HPTN 035.
The phase 2 portion of HPTN 035 was conducted as
a ‘‘lead-in’’ to the main phase 2b trial. It included the first
793 women enrolled and involved pelvic examinations
and intensive laboratory tests performed at screening and
during each of the first three months of follow-up. Phase 2
participants completed their three monthly follow-up assess-
ments for safety endpoints and data were analyzed and
presented to DSMB in line with predefined stopping rules
in the protocol. Accrual from the phase 2 portion of the
study into phase 2b continued uninterrupted at study
operation sites while also allowing a thorough review of
safety data among the smaller target population prior to full-
scale exposure of study participants to investigational study
products. Monthly colposcopic evaluations were performed
during pelvic examinations among a sub-set of 299 women
(100 in Philadelphia, USA; 82 in Durban, South Africa; 62 in
Lilongwe, Malawi; and 55 in Harare, Zimbabwe) in the Phase
2 portion. The colposcopy evaluations were performed at
sites that had a colposcopist with experience in evaluation
of female genital tract epithelium disruption. Two of the
five sites conducting colposcopy (Durban and Lilongwe)
also enrolled participants into the phase 2 study with
pelvic exams conducted by the use of naked eye without
colposcopy.
Colposcopic evaluations were performed per the CONRAD/
WHO [14]. Each participant was examined in a modified
lithotomy position. The external genitalia were examined
first, followed by insertion of a bi-valve speculum and ex-
amination of the cervix and vagina walls. For each anatomical
area, naked eye inspection was performed first, followed by
colposcopic evaluation (4 to 10magnification). If required
for complete visualization, mucus and/or cellular debris
were removed from the cervix and vaginal walls with saline
(via lavage or using large saline moistened swabs to avoid
epithelial trauma). All findings (normal and abnormal) were
recorded using terminology based on the CONRAD/WHO
manual [14]. For each exam, a determination of whether
observed findings involved disruption of blood vessels and/or
epithelial tissue was also recorded. Photographs of abnormal
epithelium were captured and stored at participating sites.
All phase 2 participants had wet mounts performed for
bacterial vaginosis (BV), candidiasis, trichomoniasis as well
as complete blood count, hepatic and renal function and
coagulation testing as part of safety monitoring. BV diagnosis
was by Nugent score. Women with asymptomatic candida
and/or asymptomatic BV were allowed entry into the study
without treatment.
Urine testing for Chlamydia trachomatis and Neisseria
gonorrhoeae (GC) with Becton Dickson Probe Tec ET strand
displacement assay was performed at study entry, and when
clinically indicated. Serologic testing for syphilis with rapid
plasma reagin screening test followed by confirmatory
microhaemagglutinin assay for treponema pallidum or tre-
ponema pallidum haemagglutination assay was performed
at study entry, annually and at study exit. Plasma stored
at study entry and study exit was tested for genital herpes
(HSV-2 antibody) with focus enzyme-linked immunosorbent
assay.
In addition to naked eye inspection and colposcopic
examination, clinically observed genital ulcers were swabbed
and tested with multiple PCR for chancroid, HSV-2 and
syphilis at the Network Central Lab (Pittsburgh, USA).
Statistical methods
Descriptive statistics were used to summarize proportions
of participants in each arm with baseline characteristics
and follow-up pelvic exam findings. Chi-squared or Fisher’s
exact tests were used to assess differences between sites
or between cohorts (colposcopy vs. naked eye). Changes
in the prevalence of findings over time were assessed by
McNemar’s test, and differences in changes over time
between two study treatment arms were assessed by Fisher’s
exact test, according to the methods of Levin and Serlin
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[15], and confidence intervals, according to Newcombe [16].
To account for the multiple testing among the pelvic exam
findings, p-values were adjusted across findings using the
false discovery rate method [17]. All analyses were per-
formed using SAS 9.1.3 (SAS Institute, Cary, NC, USA).
Results
The phase 2 portion enrolled 793 participants among whom
299 women underwent colposcopic evaluations, 75 were
assigned to BufferGel, 75 to 0.5% PRO 2000 Gel, 76 to
placebo gel and 73 to no gel. Colposcopy was performed on
all women at screening and was performed at 94% of the
897 expected monthly follow-up visits. Six (2%) participants
had no colposcopy performed during the three months of
follow-up, yielding a total of 293 women with at least one
follow-up colposcopic evaluation. Eighty-eight percent of
women underwent colposcopy at all three follow-up visits.
Baseline characteristics and follow-up findings
The 299 participants had similar characteristics at baseline
across the four study arms (Table 1a). The mean age was 30.2
years (8.7 SD), with 55% of the women aged between 18 and
29 years (varying from 48% in the No Gel arm to 69% in the
BufferGel arm, p0.03), and mean parity of 2.892.1 SD.
The majority (74%) reported that they had some secondary
education or more, varying from 6% in Lilongwe to between
86 and 99% in Durban, Harare and Philadelphia (Table 1b)
and 84% received financial support from a husband or
partner. Forty-nine percent were married (varying from 15
to 23% in Philadelphia and Durban to 94 to 98% in Harare
and Lilongwe) and 51% had a regular sexual partner. The
husband/partner mean age was 4.1 years older than the
mean age of participants. At baseline the median vaginal pH
was 4.7. Thirty-five percent had BV, syphilis (4%), gonorrhoea
(0%), Chlamydia (3%), trichomoniasis (5%) and Candida (8%).
Table 1a. Baseline demographic characteristics, sexually transmitted infections (STI), and sexual behaviour and vaginal practices of
study participants in the colposcopy cohort of the HPTN 035 trial (all sites)
BufferGel (n75) PRO 2000 Gel (n75) Placebo Gel (n76) No Gel (n73)
Baseline characteristics
Mean age, years (SD) 28.6 (8.7) 30.5 (8.8) 31.6 (9.4) 29.9 (7.6)
% Aged 18 to 29 yearsa 69% 53% 49% 48%
% Some secondary education or more 75% 71% 75% 77%
% Own Income 53% 48% 57% 45%
% Financial support from husband/partner 84% 88% 80% 85%
% Married 48% 52% 43% 52%
% Regular partner 52% 48% 57% 47%
Mean partner age, years (SD) 32.8 (9.3) 35.1 (9.8) 34.6 (9.3) 34.7 (9.3)
Mean parity (SD)b 2.4 (2.1) 3.1 (2.1) 2.8 (2.1) 2.8 (2.1)
Sexually transmitted infections
% Bacterial vaginosis (BV) by microscopyc 47% 37% 26% 30%
% BV by Amsel’s criteria 21% 23% 14% 19%
Median vaginal pH 4.7 4.7 4.7 4.7
% with homogeneous vaginal discharge 25% 19% 25% 15%
% Syphilis 3% 5% 4% 3%
% Gonorrhoea 0% 0% 0% 0%
% Chlamydia 3% 3% 1% 4%
% Trichomonas vaginalis (TV) 4% 7% 5% 3%
% Candidad 1% 11% 12% 7%
Sexual behaviour and vaginal practices
Mean (SD) # of vaginal sex acts in past seven days 2.5 (2.6) 2.5 (1.8) 2.4 (2.0) 2.5 (2.3)
% Condom use in the last sex act 53% 63% 66% 60%
% Inserted anything in vagina, past month 55% 56% 61% 55%
% Inserted water, past month 17% 12% 18% 19%
% Inserted water with vinegar (douching), past month 12% 7% 11% 8%
% Inserted water with soap, past month 7% 9% 7% 3%
% Inserted paper, cloth, cotton, etc., past monthc 5% 12% 13% 3%
% Inserted tampons, past month 24% 17% 20% 15%
% Inserted fingers, past month 15% 16% 21% 21%
aSignificant difference among arms at the p0.05 level; bBased on n199 (Data on baseline parity not collected in Philadelphia); cp0.06;
dp0.07.
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There were no statistically significant differences in genital
tract infections across study arms at baseline. However, there
were differences in BV prevalence at baseline, which varied
from 26% in the Placebo Gel arm to 47% in the BufferGel
arm (p0.06), and candida, which varied from 1% in the
BufferGel arm to 12% in the Placebo Gel arm. No statistically
significant differences were observed in BV, candidiasis and
trichomoniasis between the four study arms throughout the
three-month study period.
Colposcopic findings
Colposcopy examinations were conducted every month for
the three-month study period on 279 of the 299 colposcopy
participants. The prevalence of colposcopy pelvic exam
findings at the baseline and month 3 time points is presented
for these 279 participants in Table 2 by study treatment arm.
In general, the proportion of findings at the month 3 visit was
lower than at baseline. Overall, a colposcopic finding of
any kind was detected in 48% of participants at baseline
compared to 40% at the month 3 visit (p0.04). The rate of
erythema reduced significantly from baseline (15%) to month
3 (8%, p0.004). There were also trends towards lower rates
of abnormal vaginal discharge (16%, from 22% at baseline,
p0.06) and petechia (8% from 12% at baseline, p0.09).
On the other hand, increased rates were observed at month
3 with respect to blood from the cervical os (3%, from 1%
at baseline, p0.03) and blood-tinged discharge (2%, from
0% at baseline, p0.06). In all cases, statistical significance
at the p0.05 level and the trend towards significance
disappear when utilizing the more stringent statistical sig-
nificance levels provided by the adjustment made for
comparing multiple pelvic exam findings.
Within each study treatment arm, we also observed
changes in the rates over time for many of the individual
Table 1b. Baseline demographic characteristics, sexually transmitted infections (STI), and sexual behaviour and vaginal practices of
study participants in the colposcopy cohort of the HPTN 035 trial (per site)
Durban (n83) Lilongwe (n65) Philadelphia (n100) Zimbabwe (n51)
Baseline characteristics
Mean age, years (SD) 24.4 (4.5) 33.5 (9.3) 33.5 (9.6) 28.5 (5.4)
% Aged 18 to 29 years 82% 37% 43% 57%
% Some secondary education or more 86% 6% 99% 94%
% Own income 45% 48% 70% 27%
% Financial support from husband/partner 83% 95% 71% 100%
% Married 23% 98% 15% 94%
% Regular partner 77% 2% 84% 6%
Mean partner age, years (SD) 29.1 (4.8) 37.1 (10.6) 38.0 (11.2) 33.7 (6.1)
Mean parity (SD)a 1.5 (1.1) 4.7 (2.3)  2.3 (1.1)
Sexually transmitted infections
% Bacterial vaginosis (BV) by microscopy 22% 38% 45% 35%
% BV by Amsel’s criteria 19% 12% 17% 33%
Median vaginal pH 4.8 4.8 4.6 4.8
% with homogeneous vaginal discharge 37% 11% 16% 18%
% Syphilis 4% 3% 5% 2%
% Gonorrhoea 0% 0% 0% 0%
% Chlamydia 5% 0% 2% 4%
% Trichomonas vaginalis (TV) 2% 12% 1% 6%
% Candida 12% 5% 4% 12%
Sexual behaviour and vaginal practices
Mean (SD) # of vaginal sex acts in past seven days 1.8 (1.4) 2.5 (1.7) 2.3 (2.5) 3.8 (2.6)
% Condom use in the last sex act 65% 51% 59% 69%
% Inserted anything in vagina, past month 19% 69% 83% 49%
% Inserted water, past month 11% 15% 15% 31%
% Inserted water with vinegar (douching), past month 0% 0% 28% 0%
% Inserted water with soap, past month 4% 14% 7% 0%
% Inserted paper, cloth, cotton, etc., past month 2% 12% 6% 18%
% Inserted tampons, past month 4% 0% 52% 4%
% Inserted fingers, past month 11% 12% 26% 22%
aBased on n199 (data on baseline parity not collected in Philadelphia).
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pelvic exam findings reported in Table 2. Our analysis
addressed whether these changes over time occurred at
different rates among pairwise comparisons of active gel
arms (BufferGel, PRO 2000) compared to the control arms
(Placebo Gel, No Gel). For each finding, treatment group
differences in the rate of change of each finding from
baseline to the month 3 visit were calculated and tested
for the four pairwise comparisons of each active product with
each control arm. No significant differences were detected
in any of the pairwise comparisons of the rate of change.
For example, among the proportions of participants with
any pelvic exam finding, the rate of change from baseline
to month 3 for BufferGel, 1.4%, and for Placebo Gel,
17.4%, produce a difference of 15.9% [95% C.I.(3.9%,
36.4%), p0.16].
No statistically significant differences were observed in BV,
candidiasis and trichomoniasis between the four study arms
throughout the three-month study period. We observed no
cases of incident Chlamydia, Gonorrhoea or Syphilis during
the three-month follow-up. There were 2 cases of incident
HIV infections during the three-month study period, neither
of which was associated with any abnormal colposcopy
evaluation findings.
There were 40 participants with incident Candidiasis,
all not associated with any pelvic exam findings. With small
numbers, erythema was detected in two of the five (40%)
cases of incident Trichomoniasis cases compared to 3% of
participants without new Trichomoniasis (p0.01). Lastly,
bleeding from the site of epithelial disruption was observed
in 4 of the 78 participants (5%) with incident BV during the
three-month study period, compared to 1% without new BV
(p0.05).
Across the two sites (Durban and Lilongwe) that performed
colposcopy and naked eye without colposcopy pelvic exams
with colposcopy generally detected a significantly higher
proportion of participants with observed findings (Table 3).
A pelvic exam finding of any kind was detected during
the three-month follow-up period in 71% of colposcopy
participants compared to 41% of non-colposcopy participants
(pB0.0001). With respect to individual pelvic findings,
Table 2. Prevalence of main pelvic exam findings at baseline and at month 3 of follow-up among participants in the colposcopy
cohort of the HPTN 035 trial
BufferGel PRO 2000 Gel Placebo Gel No Gel Overall
Baseline Month 3 Baseline Month 3 Baseline Month 3 Baseline Month 3 Baseline Month 3
# Participants with colposcopy 69 69 73 73 69 69 68 68 279 279
% Participants with any pelvic exam
finding
55% 54% 44% 40% 48% 30% 46% 37% 48% 40%
% Participants with1 pelvic exam
finding
23% 12% 12% 12% 17% 10% 13% 9% 16% 11%
% Participants with:
Disrupted epithelium
Blood from cervical os 3% 3% 0% 3% 0% 1% 0% 4% 1% 3%
Abrasion 1% 1% 1% 3% 0% 0% 4% 0% 2% 1%
Deep epithelial disruption 3% 0% 0% 0% 0% 1% 3% 1% 1% 1%
Bleeding from site of epithelial
disruption
1% 0% 0% 0% 0% 1% 3% 0% 1% 0%
Intact epithelium
Abnormal vaginal discharge 28% 22% 19% 16% 28% 14% 15% 13% 22% 16%
Erythema 13% 7% 12% 10% 17% 6% 16% 7% 15% 8%
Petechia 13% 9% 12% 8% 10% 4% 12% 10% 12% 8%
Blood-tinged discharge 0% 7% 0% 1% 1% 0% 0% 0% 1% 2%
Abnormal cervical discharge 9% 1% 1% 3% 1% 3% 4% 0% 4% 2%
Ecchymosis 3% 1% 1% 0% 3% 1% 3% 4% 3% 2%
Blood in vagina-no identified
source
0% 1% 0% 3% 0% 0% 0% 0% 0% 1%
Note: The following pelvic exam findings were also observed through three months of follow-up at an overall rate of 1% or less: ulceration,
enlarged/tender inguinal lymph nodes, warts, cervical motion tenderness, abnormal cysts, laceration, peeling, and vesicles.
For each finding, treatment group differences in the rate of change of each finding from baseline to the month 3 visit were calculated and tested
for the four pairwise comparisons of each active product (BufferGel, PRO 2000 Gel) with each control arm (Placebo Gel, No Gel). No significant
differences were detected in any of the pairwise comparisons of the rates of change. For example, among the proportions of participants with
any pelvic exam finding, the rate of change from baseline to month 3 for BufferGel, 1.4%, and for Placebo Gel, 17.4%, produce a difference
of 15.9%, which has a p-value of 0.16 for the Fisher’s Exact test of the cells indicating change over time from 2x2 table for each treatment arm.
See methods of Levin and Serlin.
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use of colposcopy yielded significantly higher rates of
participants with deep epithelial disruption, bleeding from
site of epithelium disruption, erythema, petechia, blood
tinged discharge, ecchymosis and a trend towards significance
of abrasion.
Discussion
This study was the second microbicide trial designed as an
intense safety evaluation of genital epithelium disruption by
naked eye pelvic examinations together with colposcopic
evaluations and laboratory tests over an extended three-
month period unlike the classical two-week phase 1 studies
[10,11,18]. The first was COL-1492 trial, a phase 2 study that
assessed safety of multiple daily applications of nonoxynol-9
among female sex workers and colposcopy evaluations were
discontinued after finding no significant safety differences
between placebo and active product 7. However, the phase 3
portion of COL-1492 found that noxynol-9 increased risk of
HIV-1 infection compared with placebo, a finding attributable
to study gel causing higher incidence of lesions with
epithelial disruption [7]. This observation had not been
seen during colposcopic evaluations in phase 2 portion of
the study [7].
This extended safety portion of HPTN 035 demonstrated
that women in the 0.5% PRO 2000 Gel and BufferGel arms
had no significant safety signals compared to women in
the Placebo Gel and No Gel arms as evidenced by pelvic
examinations and colposcopy findings. We also observed no
statistical differences in genital tract infections across the
four arms.
The observation of at least one pelvic exam finding
at colposcopy in 48% of participants across the four arms
are consistent with reports from other previous colposcopy
studies as these are the most frequently observed outcomes
related to previous sexual intercourse [19,20]. The most
common finding of vaginal discharge found at pelvic exam-
inations among this cohort may be related to cultural practice
of douching (9% douching at baseline) and a high burden of
BV prevalence (35% at baseline). The erythematic and
petechia findings have also been observed in other cohorts
to be normal findings in vagina and cervix before insertion of
applicator or gel, and these findings disappear within a few
days without treatment [20]. Importantly, the findings of
erythema and petechia were observed in women with intact
epithelium and, therefore, had no clinical significance for
increased risk to HIV/STI acquisitions. The women (1%)
observed to have superficial ulceration and laceration at
baseline had no evidence of deep epithelium disruption and
these findings could have been attributed to be a result of
sexual trauma or other intravaginal practices also observed in
other previous studies [19]. The cumulative observation of 4%
women with deep epithelial disruption at colposcopy in the
three months of study period did not differ across arms
suggesting an uncommon finding not related to product use.
It should be noted, however, that since none of the agents
tested in this study have been shown to cause significant
toxicity, it is not known what differences in the incidence rate
of deep epithelial disruption should be assessed.
We must, however, point out the limitation of these
colposcopic findings whose significance is not completely
known and seem to have no clinical relevance for increased
Table 3. Main pelvic exam findings of colposcopy participants versus naked eye inspection participants during phase 2 portion of
the HPTN 035 trial, Durban and Lilongwe sites only
Durban Lilongwe Overall p-Value for
overall
comparisonColposcopy Naked eye Colposcopy Naked eye Colposcopy Naked eye
# Participants 82 109 62 152 144 261 
% Participants with any pelvic exam finding 73% 66% 68% 23% 71% 41% B0.0001
% Participants with 1 pelvic exam finding 13% 26% 34% 2% 22% 13% 0.01
% Participants with:
Disrupted epithelium
Blood from cervical os 5% 9% 0% 5% 3% 7% 0.10
Abrasion 2% 2% 13% 3% 7% 2% 0.02
Deep epithelial disruption 1% 0% 8% 0% 4% 0% 0.002
Bleeding from site of epithelial
disruption
0% 0% 3% 0% 1% 0% 0.06
Intact epithelium
Abnormal vaginal discharge 60% 53% 16% 7% 41% 26% 0.003
Erythema 0% 2% 32% 2% 14% 2% B0.0001
Petechia 1% 6% 34% 3% 15% 4% B0.0001
Blood-tinged discharge 2% 3% 2% 3% 2% 3% 0.71
Abnormal cervical discharge 6% 4% 8% 0% 7% 2% 0.008
Ecchymosis 1% 3% 10% 0% 5% 1% 0.04
Blood in vagina  no identified source 2% 2% 0% 0% 1% 1% 0.62
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HIV acquisitions as seen after application of N-9 [6,7].
Colposcopy picked up significantly more abnormal genital
epithelium findings than examination by naked eye (69%
compared to 51%, pB0.001). These findings commonly
termed ‘‘background noise’’ do not seem to contribute much
to detecting safety signals, and we therefore do not see
much added value in continuing to add colposcopy examina-
tions in future phase 2 topical microbicides trials. The added
cost of colposcopy procurement, training and limited utility
in predicting clinical outcome [7] does not justify its con-
tinued use in microbicide development pathway. Suggestions
to add collection of cervico-vaginal lavage specimens to
assess inflammatory changes as early safety signals have not
demonstrated significant correlation with sub-clinical inflam-
mation, and HIV acquisition thus far has remained in use in
preclinical animal models [21].
The intense extended monitoring with pelvic examina-
tions, colposcopy for three months in the first portion of
HPTN 035 provided us with evidence that there were no
safety signals of concern in the cervico-vaginal compartments
of women using BufferGel and PRO 2000 for three months of
intense follow-up. The DSMB allowed a seamless transition
from phase 2 to phase 2b after review of the safety data.
The follow-on efficacy component of the HPTN 035 study
went to completion and confirmed that both BufferGel and
PRO 2000 Gel were safe and without local genital safety
concerns [12].
Conclusions
The current clinical trial design for microbicide development
requires phase 1/2 portion of participants that have been
evaluated by colposcopy examination to detect potential
epithelial disruption from investigational product. This study
demonstrates that intense colposcopy evaluations result in
identification of non-significant clinical findings. Colposcopy
evaluations are costly, uncomfortable to participants and
therefore of questionable use in future microbicide phase 1/2
clinical trials.
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